PRESS RELEASE
Sebia Capillarys 3 TERA is now connected to Inpeco FlexLab automation
The FlexLab connection with Capillarys 3 TERA TLA represents another step ahead in the TLA expansion, opening new opportunities for Lab Automation and bringing the most popular capillary electrophoresis analyzer closer to the core clinical laboratory workflow.
Sebia launches new-generation serum free light chain (sFLC) assays for multiple myeloma testing
New test assays improve analytics and clinical coherence for the diagnosis and monitoring of multiple myeloma
Sebia announces FDA clearance for its Hydrashift 2/4 daratumumab assay
The in vitro diagnostic test, developed in collaboration with Janssen, allows for assessment of response in patients with multiple myeloma by mitigating potential interference induced by daratumumab
Sebia signs agreement with Janssen Biotech to develop a multiple myeloma IVD test
Test allows for clear results of multiple myeloma patients’ response by eliminating potential interference induced by novel therapeutic antibody
Sebia and Abingdon Health sign exclusive global distribution agreement
Sebia will distribute worldwide Seralite®-FLC serum lateral flow immunoassays for the diagnosis and monitoring of multiple myeloma
Sebia HbA1c assay now has CE mark for diagnosis of diabetes
Sebia HbA1c assay now has CE mark for diagnosis of diabetes
Sebia brings to market new Capillarys 3 Tera with CE mark
Sebia brings to market new Capillarys 3 Tera automated system with CE mark HbA1c and serum protein testing, and immunotyping
Hemoglobins Atlas
This comprehensive new medical compendium commemorates ten years of Sebia’s excellence in the field of hemoglobin separation using capillary electrophoresis
PerkinElmer to Serve as Exclusive Global Distributor
New HbA1c diabetes diagnostic technology from Sebia
New HbA1c diabetes diagnostic technology from Sebia will help laboratories facing the fast changing environment of diabetes assessment
